

CDKL5 REGISTRY

KEY STATISTICS



LAUNCH

The CDKL5 Registry was launched in 2018 after an extensive global feasibility assessment involving patient caregivers, physicians and advocates.



GLOBAL ACCESS


The CDKL5 Registry has expanded internationally! The registry is currently available in French, Italian, German, English and Spanish.

Additional languages, including Arabic, Chinese, Russian and Japanese are in development.



2 INITIAL FOUNDERS

The CDKL5 Registry was created in collaboration with the Loulou Foundation, a non-profit focused on advancing CDKL5 research and development of therapeutics for CDKL5 Deficiency Disorder, and the Orphan Disease Center at the University of Pennsylvania's Perelman School of Medicine.



ACHIEVEMENTS

Multiple pharmaceutical companies working to develop treatments for CDKL5 Deficiency Disorder (CDD).

The formation of an unprecedented pre-competitive industry consortium and launch of the CANDID Study.



PATIENTS ENROLLED

Since its launch, the CDKL5 Registry has enrolled over 130 patients. With the release of multiple languages in 2022, enrollment is anticipated to increase dramatically across the world.

Learn More and Enroll in the CDKL5 Registry
WWW.CDKL5REGISTRY.ORG

Learn About Pulse Inframe's Platform that Powers this Registry
www.pulseinframe.com